Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 19Recruiting 4Unknown 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Plasma cell 2Lymphoid 1Head & Neck 1Gynecologic 1Classical hematology 1Breast 1

Conditions

Multiple Myeloma 339Neoplasms, Plasma Cell 62Lymphoma 38Recurrence 27Leukemia 26Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 20Hodgkin Disease 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 17Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Follicular 16Lymphoma, Large B-Cell, Diffuse 15Immunoglobulin Light-chain Amyloidosis 14Lymphoma, B-Cell, Marginal Zone 13Hematologic Neoplasms 13Lymphoma, Mantle-Cell 12Burkitt Lymphoma 12Lymphoma, Large-Cell, Immunoblastic 10Neoplasms 8Myeloproliferative Disorders 8Leukemia, Myeloid, Chronic-Phase 8Leukemia, Myeloid, Accelerated Phase 8Blast Crisis 8Neoplasm, Residual 7Hematologic Diseases 7Pancreatic Neoplasms 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6Lung Neoplasms 6

Interventions

isatuximab 2Dexamethasone 2pomalidomide 1Ranitidine 1Lenalidomide 1Diphenhydramine 1Cyclophosphamide 1Bortezomib 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Renal Insufficiency × Plasma cell × Clear all
NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡